• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Inspire files for $86.25M IPO

biospectrumasiaApril 10, 2018

Tag: IPO , Inspire

The Maple Grove-based company, Inspire Medical Systems, which sells its proprietary Inspire therapy for sleep apnea, has filed for an initial public offering seeking up to $86.25M.

BofA Merrill Lynch and Goldman Sachs are the joint bookrunners on the deal. For the year ended Dec. 31, 2017, the company posted $28.6M in revenue, with $22.55M of that going through as gross profit.

Register as Visitor to CPhI China 2018!

Previous:Protalex Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia

Next:Thermo Fisher collaborates with Ortho Clinical Diagnostics

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Inspire files for $86.25M IPO | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Annexin A1 (1-25) (dephosphorylated)/Annexin-1 (2-26) (human)/Lipocortin-1 (2-26)/ Calpactin II (1-2

Annexin A1 (1-25) (dephosphorylated)/Annexin-1 (2-26) (human)/Lipocortin-1 (2-26)/ Calpactin II (1-2
HPEx-L1  HAND PUSH LIPOSOME EXTRUDER

HPEx-L1  HAND PUSH LIPOSOME EXTRUDER
Teniposide

Teniposide
Liposomal β-CAROTENE

Liposomal β-CAROTENE
Sodium Tripolyphosphate (STPP)

Sodium Tripolyphosphate (STPP)
Tripotassium Phosphate

Tripotassium Phosphate
Siponimod

Siponimod
dipotassium trioxotellurate

dipotassium trioxotellurate
Liposoaml phytosqualane

Liposoaml phytosqualane
24-carbonyl-1,3-bi-TBS-trans-Calcipotriol

24-carbonyl-1,3-bi-TBS-trans-Calcipotriol

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service